Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million
- Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel s RIP1 inhibitor program
- Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients
- Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021
- Conference call and webcast today at 4:30PM Eastern Time
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE
INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biden Administration secures supply of new COVID-19 therapeutic treatment The treatment uses two monoclonal antibodies, bamlanivimab and etesevimab, to treat nonhospitalized high-risk COVID-19 patients.
, Associate Editor
As of Friday, the Biden Administration has secured a supply of a recently authorized COVID-19 therapeutic treatment, with the U.S. Department of Health and Human Services and the Department of Defense collaborating to purchase 100,000 courses of a second treatment from Eli Lilly and Company.
The treatment uses two monoclonal antibodies, bamlanivimab and etesevimab, to treat non-hospitalized, high-risk COVID-19 patients.
The U.S. Food and Drug Administration issued emergency use authorization for Eli Lilly s therapeutic of bamlanivimab and etesevimab on February 9. The treatment is administered through an intravenous infusion and is intended for nonhospitalized patients with confirmed COVID-19 who are experiencing mild to moderate symptoms and ar
CEPI partner INOVIO launches Lassa vaccine Phase I trial in West Africa ghanavisions.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ghanavisions.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, in Ghana. The Phase 1B clinical trial (LSV-002), ongoing at the Noguchi Memorial Institute for Medical Research in Accra, Ghana, is the first vaccine clinical trial for Lassa fever to be conducted in West Africa, where the infection is endemic. INO-4500 is also the first vaccine candidate for Lassa fever to enter human trials.